Crossmark Global Holdings Inc. raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 540,220 shares of the biopharmaceutical company's stock after acquiring an additional 8,741 shares during the quarter. Gilead Sciences makes up approximately 0.9% of Crossmark Global Holdings Inc.'s investment portfolio, making the stock its 16th largest position. Crossmark Global Holdings Inc.'s holdings in Gilead Sciences were worth $49,900,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently made changes to their positions in GILD. FMR LLC lifted its holdings in shares of Gilead Sciences by 79.4% in the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company's stock worth $2,780,329,000 after acquiring an additional 14,680,161 shares during the last quarter. Wellington Management Group LLP raised its holdings in Gilead Sciences by 50.9% in the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company's stock valued at $2,900,921,000 after buying an additional 11,665,593 shares during the last quarter. Point72 Asset Management L.P. raised its holdings in Gilead Sciences by 350.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company's stock valued at $193,274,000 after buying an additional 1,793,145 shares during the last quarter. International Assets Investment Management LLC raised its holdings in Gilead Sciences by 8,238.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company's stock valued at $137,708,000 after buying an additional 1,622,806 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C bought a new position in Gilead Sciences in the 2nd quarter valued at approximately $102,298,000. Institutional investors own 83.67% of the company's stock.
Gilead Sciences Stock Up 1.2 %
NASDAQ:GILD traded up $1.12 during trading hours on Tuesday, hitting $92.96. 10,544,871 shares of the company traded hands, compared to its average volume of 7,055,390. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The firm's 50-day simple moving average is $91.65 and its 200-day simple moving average is $84.38. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $98.90. The company has a market cap of $115.85 billion, a PE ratio of 1,032.89, a PEG ratio of 1.29 and a beta of 0.18.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts' consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company had revenue of $7.55 billion for the quarter, compared to analysts' expectations of $7.01 billion. During the same period in the previous year, the business posted $2.29 EPS. The business's revenue for the quarter was up 7.0% compared to the same quarter last year. Equities analysts predict that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.
Gilead Sciences Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were issued a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 3.31%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences's dividend payout ratio (DPR) is currently 3,422.22%.
Analyst Ratings Changes
A number of brokerages recently issued reports on GILD. Morgan Stanley upgraded shares of Gilead Sciences from an "equal weight" rating to an "overweight" rating and raised their price objective for the company from $87.00 to $113.00 in a report on Friday, January 10th. Citigroup began coverage on shares of Gilead Sciences in a report on Thursday, November 14th. They issued a "buy" rating and a $125.00 price objective for the company. BMO Capital Markets raised their price objective on shares of Gilead Sciences from $94.00 to $102.00 and gave the company an "outperform" rating in a report on Thursday, November 7th. Robert W. Baird increased their target price on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a "neutral" rating in a research report on Thursday, November 7th. Finally, Daiwa America raised shares of Gilead Sciences to a "hold" rating in a research report on Monday, November 18th. Eleven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $97.96.
Check Out Our Latest Analysis on Gilead Sciences
Insider Buying and Selling
In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the transaction, the director now owns 8,920 shares of the company's stock, valued at $815,198.80. The trade was a 43.21 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now directly owns 129,873 shares of the company's stock, valued at $11,863,898.55. The trade was a 1.89 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 456,234 shares of company stock valued at $42,130,461. 0.29% of the stock is owned by insiders.
Gilead Sciences Company Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
See Also
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report